Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
Dendritic cell (DC) based cancer immunotherapy aims at the activation of the immune system, and in particular tumor-specific cytotoxic T lymphocytes (CTLs) to eradicate the tumor. DCs represent a heterogeneous cell population, including conventional DCs (cDCs), consisting of cDC1s, cDC2s, plasmacyto...
Main Authors: | Anne Huber, Floris Dammeijer, Joachim G. J. V. Aerts, Heleen Vroman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02804/full |
Similar Items
-
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
by: Mandy van Gulijk, et al.
Published: (2018-12-01) -
Between biology and medicine: perspectives on the use of dendritic cells in anticancer therapy
by: Agnieszka Szczygieł, et al.
Published: (2017-11-01) -
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
by: Robert A. Belderbos, et al.
Published: (2020-06-01) -
Determination of T Follicular Helper Cell Fate by Dendritic Cells
by: Jayendra Kumar Krishnaswamy, et al.
Published: (2018-09-01) -
Cord-Blood-Stem-Cell-Derived Conventional Dendritic Cells Specifically Originate from CD115-Expressing Precursors
by: Maud Plantinga, et al.
Published: (2019-02-01)